Paritaprevir
TECHNIVIE
What it isHCV NS3/4A protease inhibitor given with ritonavir; hepatitis C.
Why this oneRitonavir boosting allowed once-daily dosing of an otherwise short-lived protease inhibitor.
What limits itContraindicated in decompensated cirrhosis. Superseded; extensive CYP3A4 interactions.
FDA-approved for
- chronic hepatitis C (2014)
NO BOXED WARNINGS
Principal riskContraindicated in decompensated cirrhosis
Classes and tags
Clinical profile
Mechanism of action: Paritaprevir ballicule
